These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1512 related articles for article (PubMed ID: 28410560)
1. Role of Long-Acting Muscarinic Antagonist/Long-Acting β Petite SE Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560 [TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Long-Acting Beta Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405 [TBL] [Abstract][Full Text] [Related]
3. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Oba Y; Keeney E; Ghatehorde N; Dias S Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859 [TBL] [Abstract][Full Text] [Related]
5. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019 [TBL] [Abstract][Full Text] [Related]
6. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Horita N; Goto A; Shibata Y; Ota E; Nakashima K; Nagai K; Kaneko T Cochrane Database Syst Rev; 2017 Feb; 2(2):CD012066. PubMed ID: 28185242 [TBL] [Abstract][Full Text] [Related]
8. Inhaled corticosteroids with combination inhaled long-acting beta Tan DJ; White CJ; Walters JA; Walters EH Cochrane Database Syst Rev; 2016 Nov; 11(11):CD011600. PubMed ID: 27830584 [TBL] [Abstract][Full Text] [Related]
9. Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids. Liao PA; Pan SW; Chen CY; Deng CY; Dong YH Int J Chron Obstruct Pulmon Dis; 2023; 18():553-563. PubMed ID: 37069844 [TBL] [Abstract][Full Text] [Related]
10. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease. van Geffen WH; Tan DJ; Walters JA; Walters EH Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551 [TBL] [Abstract][Full Text] [Related]
11. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study. Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104 [TBL] [Abstract][Full Text] [Related]
12. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120 [TBL] [Abstract][Full Text] [Related]
13. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease. Sliwka A; Jankowski M; Gross-Sondej I; Storman M; Nowobilski R; Bala MM Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012355. PubMed ID: 30141826 [TBL] [Abstract][Full Text] [Related]
14. Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA Ann Pharmacother; 2017 Nov; 51(11):945-953. PubMed ID: 28677404 [TBL] [Abstract][Full Text] [Related]
15. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102 [TBL] [Abstract][Full Text] [Related]
16. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939 [TBL] [Abstract][Full Text] [Related]
17. Long-acting muscarinic antagonist and long-acting β Buhl R; Miravitlles M; Anzueto A; Brunton S Ther Adv Respir Dis; 2024; 18():17534666241279115. PubMed ID: 39352722 [TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers? Tariq SM; Thomas EC Int J Chron Obstruct Pulmon Dis; 2017; 12():1877-1882. PubMed ID: 28694698 [TBL] [Abstract][Full Text] [Related]
19. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514 [TBL] [Abstract][Full Text] [Related]
20. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Kew KM; Dias S; Cates CJ Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]